14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma

CH Lee, WB Ou, A Mariņo-Enriquez… - Proceedings of the …, 2012 - National Acad Sciences
CH Lee, WB Ou, A Mariņo-Enriquez, M Zhu, M Mayeda, Y Wang, X Guo, AL Brunner…
Proceedings of the National Academy of Sciences, 2012National Acad Sciences
14-3-3 proteins are ubiquitously expressed regulators of various cellular functions, including
proliferation, metabolism, and differentiation, and altered 14-3-3 expression is associated
with development and progression of cancer. We report a transforming 14-3-3 oncoprotein,
which we identified through conventional cytogenetics and whole-transcriptome sequencing
analysis as a highly recurrent genetic mechanism in a clinically aggressive form of uterine
sarcoma: high-grade endometrial stromal sarcoma (ESS). The 14-3-3 oncoprotein results …
14-3-3 proteins are ubiquitously expressed regulators of various cellular functions, including proliferation, metabolism, and differentiation, and altered 14-3-3 expression is associated with development and progression of cancer. We report a transforming 14-3-3 oncoprotein, which we identified through conventional cytogenetics and whole-transcriptome sequencing analysis as a highly recurrent genetic mechanism in a clinically aggressive form of uterine sarcoma: high-grade endometrial stromal sarcoma (ESS). The 14-3-3 oncoprotein results from a t(10;17) genomic rearrangement, leading to fusion between 14-3-3ε (YWHAE) and either of two nearly identical FAM22 family members (FAM22A or FAM22B). Expression of YWHAE–FAM22 fusion oncoproteins was demonstrated by immunoblot in t(10;17)-bearing frozen tumor and cell line samples. YWHAE–FAM22 fusion gene knockdowns were performed with shRNAs and siRNAs targeting various FAM22A exons in an t(10;17)-bearing ESS cell line (ESS1): Fusion protein expression was inhibited, with corresponding reduction in cell growth and migration. YWHAE–FAM22 maintains a structurally and functionally intact 14-3-3ε (YWHAE) protein-binding domain, which is directed to the nucleus by a FAM22 nuclear localization sequence. In contrast to classic ESS, harboring JAZF1 genetic fusions, YWHAE–FAM22 ESS display high-grade histologic features, a distinct gene-expression profile, and a more aggressive clinical course. Fluorescence in situ hybridization analysis demonstrated absolute specificity of YWHAE–FAM22A/B genetic rearrangement for high-grade ESS, with no fusions detected in other uterine and nonuterine mesenchymal tumors (55 tumor types, n = 827). These discoveries reveal diagnostically and therapeutically relevant models for characterizing aberrant 14-3-3 oncogenic functions.
National Acad Sciences